Colorectal Cancer

News alerts, weekly reports and conference planners

Related cancers:

‹

Solid Tumor (16201)

Colon Cancer (169)

Rectal Cancer (89)

Colorectal Adenocarcinoma (9)

Solid Tumor (16201)

Colon Cancer (169)

Rectal Cancer (89)

Colorectal Adenocarcinoma (9)

›

HER-2 positive	Colorectal Cancer	HER-2 positive	Colorectal Cancer	pertuzumab/trastuzumab/hyaluronidase-zzxf Sensitive: A1 - Approval Chugai Press Release - 3 days (New A1) pertuzumab / trastuzumab / hyaluronidase-zzxf Sensitive : A1 Chugai Press Release - 3d	pertuzumab/trastuzumab/hyaluronidase-zzxf Sensitive: A1 - Approval Chugai Press Release - 3 days pertuzumab / trastuzumab / hyaluronidase-zzxf Sensitive : A1 Chugai Press Release - 3 days - (New A1)
KRAS G12C	Rectal Cancer	KRAS G12C	Rectal Cancer	panitumumab + sotorasib Sensitive: A2 - Guideline NCCN - 1 week (New A2) panitumumab + sotorasib Sensitive : A2 NCCN - 1wk	panitumumab + sotorasib Sensitive: A2 - Guideline NCCN - 1 week panitumumab + sotorasib Sensitive : A2 NCCN - 1 week - (New A2)
KRAS G12C	Rectal Cancer	KRAS G12C	Rectal Cancer	cetuximab + sotorasib Sensitive: A2 - Guideline NCCN - 1 week (New A2) cetuximab + sotorasib Sensitive : A2 NCCN - 1wk	cetuximab + sotorasib Sensitive: A2 - Guideline NCCN - 1 week cetuximab + sotorasib Sensitive : A2 NCCN - 1 week - (New A2)
KRAS G12C	Rectal Cancer	KRAS G12C	Rectal Cancer	panitumumab + adagrasib Sensitive: A2 - Guideline NCCN - 1 week (New A2) panitumumab + adagrasib Sensitive : A2 NCCN - 1wk	panitumumab + adagrasib Sensitive: A2 - Guideline NCCN - 1 week panitumumab + adagrasib Sensitive : A2 NCCN - 1 week - (New A2)
KRAS G12C	Rectal Cancer	KRAS G12C	Rectal Cancer	cetuximab + adagrasib Sensitive: A2 - Guideline NCCN - 1 week (New A2) cetuximab + adagrasib Sensitive : A2 NCCN - 1wk	cetuximab + adagrasib Sensitive: A2 - Guideline NCCN - 1 week cetuximab + adagrasib Sensitive : A2 NCCN - 1 week - (New A2)
KRAS G12C	Colon Cancer	KRAS G12C	Colon Cancer	panitumumab + sotorasib Sensitive: A2 - Guideline NCCN - 1 week (New A2) panitumumab + sotorasib Sensitive : A2 NCCN - 1wk	panitumumab + sotorasib Sensitive: A2 - Guideline NCCN - 1 week panitumumab + sotorasib Sensitive : A2 NCCN - 1 week - (New A2)
KRAS G12C	Colon Cancer	KRAS G12C	Colon Cancer	cetuximab + sotorasib Sensitive: A2 - Guideline NCCN - 1 week (New A2) cetuximab + sotorasib Sensitive : A2 NCCN - 1wk	cetuximab + sotorasib Sensitive: A2 - Guideline NCCN - 1 week cetuximab + sotorasib Sensitive : A2 NCCN - 1 week - (New A2)
KRAS G12C	Colon Cancer	KRAS G12C	Colon Cancer	panitumumab + adagrasib Sensitive: A2 - Guideline NCCN - 1 week (New A2) panitumumab + adagrasib Sensitive : A2 NCCN - 1wk	panitumumab + adagrasib Sensitive: A2 - Guideline NCCN - 1 week panitumumab + adagrasib Sensitive : A2 NCCN - 1 week - (New A2)
MSI-H/dMMR	Colorectal Cancer	MSI-H/dMMR	Colorectal Cancer	pembrolizumab Sensitive: A1 - Approval NICE - 1 week (New A2) pembrolizumab Sensitive : A1 NICE - 1wk	pembrolizumab Sensitive: A1 - Approval NICE - 1 week pembrolizumab Sensitive : A1 NICE - 1 week - (New A2)
KRAS G12C	Colon Cancer	KRAS G12C	Colon Cancer	cetuximab + adagrasib Sensitive: A2 - Guideline NCCN - 1 week (New A2) cetuximab + adagrasib Sensitive : A2 NCCN - 1wk	cetuximab + adagrasib Sensitive: A2 - Guideline NCCN - 1 week cetuximab + adagrasib Sensitive : A2 NCCN - 1 week - (New A2)
BRAF V600E	Colorectal Cancer	BRAF V600E	Colorectal Cancer	bevacizumab Sensitive: C2 – Inclusion Criteria J Geriatr Oncol - 1 week (New C3) bevacizumab Sensitive : C2 J Geriatr Oncol - 1wk	bevacizumab Sensitive: C2 – Inclusion Criteria J Geriatr Oncol - 1 week bevacizumab Sensitive : C2 J Geriatr Oncol - 1 week - (New C3)
RAS wild-type + BRAF wild-type	Colorectal Cancer	RAS wild-type + BRAF wild-type	Colorectal Cancer	cetuximab Sensitive: C2 – Inclusion Criteria Med Princ Pract - 1 week (New C3) cetuximab Sensitive : C2 Med Princ Pract - 1wk	cetuximab Sensitive: C2 – Inclusion Criteria Med Princ Pract - 1 week cetuximab Sensitive : C2 Med Princ Pract - 1 week - (New C3)
MSI-H/dMMR	Colorectal Cancer	MSI-H/dMMR	Colorectal Cancer	Immunotherapy Sensitive: C3 – Early Trials Clin Cancer Res - 1 week (New C3) Immunotherapy Sensitive : C3 Clin Cancer Res - 1wk	Immunotherapy Sensitive: C3 – Early Trials Clin Cancer Res - 1 week Immunotherapy Sensitive : C3 Clin Cancer Res - 1 week - (New C3)
RAS wild-type	Colorectal Cancer	RAS wild-type	Colorectal Cancer	ramucirumab Sensitive: C2 – Inclusion Criteria ESMO Open - 2 weeks (New C3) ramucirumab Sensitive : C2 ESMO Open - 2wk	ramucirumab Sensitive: C2 – Inclusion Criteria ESMO Open - 2 weeks ramucirumab Sensitive : C2 ESMO Open - 2 weeks - (New C3)
miR-18a overexpression	Colorectal Cancer	miR-18a overexpression	Colorectal Cancer	FOLFOX Sensitive: C3 – Early Trials Cancer Rep (Hoboken) - 2 weeks (New C3) FOLFOX Sensitive : C3 Cancer Rep (Hoboken) - 2wk	FOLFOX Sensitive: C3 – Early Trials Cancer Rep (Hoboken) - 2 weeks FOLFOX Sensitive : C3 Cancer Rep (Hoboken) - 2 weeks - (New C3)
KRAS mutation	Colorectal Cancer	KRAS mutation	Colorectal Cancer	bevacizumab Sensitive: B - Late Trials Nat Commun - 3 weeks (New B) bevacizumab Sensitive : B Nat Commun - 3wk	bevacizumab Sensitive: B - Late Trials Nat Commun - 3 weeks bevacizumab Sensitive : B Nat Commun - 3 weeks - (New B)
KRAS wild-type	Colorectal Cancer	KRAS wild-type	Colorectal Cancer	cetuximab Sensitive: B - Late Trials Nat Commun - 3 weeks (New B) cetuximab Sensitive : B Nat Commun - 3wk	cetuximab Sensitive: B - Late Trials Nat Commun - 3 weeks cetuximab Sensitive : B Nat Commun - 3 weeks - (New B)
BRAF wild-type	Colorectal Cancer	BRAF wild-type	Colorectal Cancer	anlotinib Sensitive: C2 – Inclusion Criteria Front Oncol - 3 weeks (New C3) anlotinib Sensitive : C2 Front Oncol - 3wk	anlotinib Sensitive: C2 – Inclusion Criteria Front Oncol - 3 weeks anlotinib Sensitive : C2 Front Oncol - 3 weeks - (New C3)
RAS wild-type	Colorectal Cancer	RAS wild-type	Colorectal Cancer	anlotinib Sensitive: C3 – Early Trials Front Oncol - 3 weeks (New C3) anlotinib Sensitive : C3 Front Oncol - 3wk	anlotinib Sensitive: C3 – Early Trials Front Oncol - 3 weeks anlotinib Sensitive : C3 Front Oncol - 3 weeks - (New C3)
RAS mutation	Colorectal Cancer	RAS mutation	Colorectal Cancer	durvalumab + tremelimumab Sensitive: C3 – Early Trials Oncology - 3 weeks (New C3) durvalumab + tremelimumab Sensitive : C3 Oncology - 3wk	durvalumab + tremelimumab Sensitive: C3 – Early Trials Oncology - 3 weeks durvalumab + tremelimumab Sensitive : C3 Oncology - 3 weeks - (New C3)
MSI-H/dMMR	Colorectal Cancer	MSI-H/dMMR	Colorectal Cancer	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
BRAF V600E	Colorectal Cancer	BRAF V600E	Colorectal Cancer	cetuximab + binimetinib + encorafenib Sensitive: A1 - Approval cetuximab + binimetinib + encorafenib Sensitive : A1	cetuximab + binimetinib + encorafenib Sensitive: A1 - Approval cetuximab + binimetinib + encorafenib Sensitive : A1
BRAF V600E	Colorectal Cancer	BRAF V600E	Colorectal Cancer	cetuximab + encorafenib Sensitive: A1 - Approval cetuximab + encorafenib Sensitive : A1	cetuximab + encorafenib Sensitive: A1 - Approval cetuximab + encorafenib Sensitive : A1
No biomarker	Colon Cancer	No biomarker	Colon Cancer	capecitabine Sensitive: A1 - Approval capecitabine Sensitive : A1	capecitabine Sensitive: A1 - Approval capecitabine Sensitive : A1
No biomarker	Rectal Cancer	No biomarker	Rectal Cancer	FOLFIRI Sensitive: A1 - Approval FOLFIRI Sensitive : A1	FOLFIRI Sensitive: A1 - Approval FOLFIRI Sensitive : A1
No biomarker	Colon Cancer	No biomarker	Colon Cancer	5-fluorouracil + irinotecan Sensitive: A1 - Approval 5-fluorouracil + irinotecan Sensitive : A1	5-fluorouracil + irinotecan Sensitive: A1 - Approval 5-fluorouracil + irinotecan Sensitive : A1
No biomarker	Colorectal Cancer	No biomarker	Colorectal Cancer	bevacizumab Sensitive: A1 - Approval bevacizumab Sensitive : A1	bevacizumab Sensitive: A1 - Approval bevacizumab Sensitive : A1
No biomarker	Rectal Cancer	No biomarker	Rectal Cancer	bevacizumab-awwb Sensitive: A1 - Approval bevacizumab-awwb Sensitive : A1	bevacizumab-awwb Sensitive: A1 - Approval bevacizumab-awwb Sensitive : A1
No biomarker	Colon Cancer	No biomarker	Colon Cancer	bevacizumab-awwb Sensitive: A1 - Approval bevacizumab-awwb Sensitive : A1	bevacizumab-awwb Sensitive: A1 - Approval bevacizumab-awwb Sensitive : A1
No biomarker	Colon Cancer	No biomarker	Colon Cancer	bevacizumab-bvzr Resistant: A1 - Approval bevacizumab-bvzr Resistant : A1	bevacizumab-bvzr Resistant: A1 - Approval bevacizumab-bvzr Resistant : A1
No biomarker	Colorectal Cancer	No biomarker	Colorectal Cancer	trifluridine/tipiracil Sensitive: A1 - Approval trifluridine / tipiracil Sensitive : A1	trifluridine/tipiracil Sensitive: A1 - Approval trifluridine / tipiracil Sensitive : A1
No biomarker	Colorectal Cancer	No biomarker	Colorectal Cancer	ziv-aflibercept IV Sensitive: A1 - Approval ziv-aflibercept IV Sensitive : A1	ziv-aflibercept IV Sensitive: A1 - Approval ziv-aflibercept IV Sensitive : A1
No biomarker	Colorectal Cancer	No biomarker	Colorectal Cancer	capecitabine Sensitive: A1 - Approval capecitabine Sensitive : A1	capecitabine Sensitive: A1 - Approval capecitabine Sensitive : A1
EGFR expression	Colorectal Cancer	EGFR expression	Colorectal Cancer	cetuximab Sensitive: A1 - Approval cetuximab Sensitive : A1	cetuximab Sensitive: A1 - Approval cetuximab Sensitive : A1
KRAS Q61	Colorectal Cancer	KRAS Q61	Colorectal Cancer	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1
No biomarker	Colorectal Cancer	No biomarker	Colorectal Cancer	ramucirumab Sensitive: A1 - Approval ramucirumab Sensitive : A1	ramucirumab Sensitive: A1 - Approval ramucirumab Sensitive : A1
KRAS A146	Colorectal Cancer	KRAS A146	Colorectal Cancer	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1
No biomarker	Rectal Cancer	No biomarker	Rectal Cancer	irinotecan Sensitive: A1 - Approval irinotecan Sensitive : A1	irinotecan Sensitive: A1 - Approval irinotecan Sensitive : A1
No biomarker	Colon Cancer	No biomarker	Colon Cancer	irinotecan Sensitive: A1 - Approval irinotecan Sensitive : A1	irinotecan Sensitive: A1 - Approval irinotecan Sensitive : A1
KRAS G13	Colorectal Cancer	KRAS G13	Colorectal Cancer	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1
KRAS G12	Colorectal Cancer	KRAS G12	Colorectal Cancer	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1
No biomarker	Colorectal Cancer	No biomarker	Colorectal Cancer	Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval Aybintio (bevacizumab biosimilar) Sensitive : A1	Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval Aybintio (bevacizumab biosimilar) Sensitive : A1
MSI-H/dMMR	Colorectal Cancer	MSI-H/dMMR	Colorectal Cancer	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Colorectal Cancer	No biomarker	Colorectal Cancer	regorafenib Sensitive: A1 - Approval regorafenib Sensitive : A1	regorafenib Sensitive: A1 - Approval regorafenib Sensitive : A1
KRAS K117	Colorectal Cancer	KRAS K117	Colorectal Cancer	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1
KRAS A59	Colorectal Cancer	KRAS A59	Colorectal Cancer	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1
KRAS G12S	Colorectal Cancer	KRAS G12S	Colorectal Cancer	panitumumab Resistant: A1 - Approval panitumumab Resistant : A1	panitumumab Resistant: A1 - Approval panitumumab Resistant : A1
NRAS Q61	Colorectal Cancer	NRAS Q61	Colorectal Cancer	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1
NRAS Q61	Colorectal Cancer	NRAS Q61	Colorectal Cancer	panitumumab Resistant: A1 - Approval panitumumab Resistant : A1	panitumumab Resistant: A1 - Approval panitumumab Resistant : A1
NRAS G13	Colorectal Cancer	NRAS G13	Colorectal Cancer	panitumumab Resistant: A1 - Approval panitumumab Resistant : A1	panitumumab Resistant: A1 - Approval panitumumab Resistant : A1
NRAS G13	Colorectal Cancer	NRAS G13	Colorectal Cancer	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1
NRAS G12	Colorectal Cancer	NRAS G12	Colorectal Cancer	panitumumab Resistant: A1 - Approval panitumumab Resistant : A1	panitumumab Resistant: A1 - Approval panitumumab Resistant : A1

Colorectal Cancer

Associations(1343)

Associations
(1343)